Welcome to our dedicated page for Chromadex news (Ticker: CDXC), a resource for investors and traders seeking the latest updates and insights on Chromadex stock.
ChromaDex Corp. (CDXC) delivers science-backed innovations in healthy aging through its NAD+ research and nutraceutical products. This news hub provides investors and industry stakeholders with essential updates on the company's scientific advancements, regulatory milestones, and market developments.
Access timely press releases covering clinical trial results, patent approvals, and strategic partnerships with research institutions. Track updates across ChromaDex's three core segments: consumer supplements, ingredient licensing, and analytical services supporting product quality assurance.
Our curated news collection enables efficient monitoring of CDXC's progress in translating biochemical research into commercial applications. Bookmark this page for direct access to earnings announcements, product launch details, and peer-reviewed study publications – all critical for evaluating the company's position in the bioscience sector.
ChromaDex (NASDAQ: CDXC) will participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024. The company's CEO, Rob Fried, and CFO, Brianna Gerber, will engage in virtual one-on-one meetings throughout the event. Interested parties can arrange meetings by contacting Lytham Partners or registering on their website.
ChromaDex (NASDAQ:CDXC) announced that its Niagen® ingredient has won the NutraIngredients EU Healthy Ageing Ingredient of the Year Award. Niagen, a patented nicotinamide riboside (NR) and the active ingredient in Tru Niagen®, was recognized for its high-quality research and significant contributions to healthy aging. The award highlights Niagen’s impact on cellular health and its potential to support longevity across various generations. ChromaDex's CEO, Rob Fried, expressed honor in receiving the award, emphasizing their mission to tackle aging through NAD+ augmentation. Niagen is backed by extensive research, including studies from two Nobel Prize winners and over 300 published scientific papers.
ChromaDex (NASDAQ:CDXC) reported first quarter 2024 financial results with total net sales of $22.2 million, gross margin of 60.7%, a net loss of $0.5 million, and positive Adjusted EBITDA of $0.7 million. The company reiterated a full-year outlook with net sales growth of at least 16%. Tru Niagen® contributed $17.4 million to total net sales, and ChromaDex expanded distribution through partnerships with The Vitamin Shoppe and Sprouts Farmers Market. Operating expenses decreased, net loss improved, and Adjusted EBITDA turned positive. The company aims for revenue growth, gross margin improvement, and increased investments in research and development, marketing, and product launches.
ChromaDex announces an ingredient partnership with Solgar, a Nestlé Health Science brand, introducing Solgar Cellular Energy supplement featuring ChromaDex's NIAGEN NR. The collaboration aims to boost NAD+ levels for cellular health, highlighting NIAGEN as the gold standard in NAD+ supplements. NIAGEN NR, supported by extensive research, increases NAD+ by over 50% in two weeks. Solgar Cellular Energy also includes B vitamins and vitamin C for comprehensive health benefits.
FAQ
What is the current stock price of Chromadex (CDXC)?
What is the market cap of Chromadex (CDXC)?
